Structural characterisation of the co-inhibitory complex formed by the tumour suppressor PTEN and the metastatic factor PREX2

肿瘤抑制因子 PTEN 和转移因子 PREX2 形成的共抑制复合物的结构表征

• 批准号: nhmrc : GNT1146578
• 负责人: A/Pr Hans Elmlund
• 金额: $ 55.58万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/structural-characterisation-co-factor-prex2/1348769
• 关键词: Structural; characterisation; co; inhibitory; complex

Metastasis is a major cause of cancer mortality. Characterisation of key proteins that regulate metastasis is therefore a priority. PTEN and PREX2 are enzymes that play key roles in metastasis in melanoma, and other cancers. We will determine the structural basis of PTEN:PREX2 co-inhibition, and determine how cancer-associated PREX2 mutations dysregulate this inhibitory complex. This study will provide the necessary knowledge for future drug development programs targeting PTEN:PREX2 in cancer.

转移是癌症死亡的主要原因。因此，确定调控转移的关键蛋白是当务之急。PTEN和PREX2是在黑色素瘤和其他癌症的转移中起关键作用的酶。我们将确定PTEN:PREX2共抑制的结构基础，并确定癌症相关的PREX2突变如何失调这种抑制复合物。该研究将为未来针对PTEN:PREX2的癌症药物开发项目提供必要的知识。